Bristol-Myers Off The Hook In Plavix Probe

Law360, New York (February 27, 2007, 12:00 AM EST) -- Bristol-Myers Squibb Co. said a federal investigation found no violations of securities laws stemming from the company's actions in negotiating a patent settlement over blockbuster drug Plavix last year.

The drug maker said in a filing with the U.S. Securities and Exchange Commission on Monday that the Office of the U.S. Attorney for the District of New Jersey had found no securities law violations and did not intend to take further action regarding Bristol-Myers’s deferred-prosecution agreement, set to expire in June.

However, the company hasn’t been...
To view the full article, register now.